Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation

Colombo, 2006, Ovarian cancer, Crit Rev Oncol Hematol, 60, 159, 10.1016/j.critrevonc.2006.03.004 Shih Ie, 2005, Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges, Clin Cancer Res, 11, 7273, 10.1158/1078-0432.CCR-05-0755 Shih Ie, 2004, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis, Am J Pathol, 164, 1511, 10.1016/S0002-9440(10)63708-X Jemal, 2004, Cancer statistics, 2004, CA Cancer J Clin, 54, 8, 10.3322/canjclin.54.1.8 Stuart, 2003, First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer, Gynecol Oncol, 90, S8, 10.1016/S0090-8258(03)00472-4 Moos, 1988, Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin, Nature, 334, 701, 10.1038/334701a0 Schachner, 1997, Neural recognition molecules and synaptic plasticity, Curr Opin Cell Biol, 9, 627, 10.1016/S0955-0674(97)80115-9 Brummendorf, 1998, Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations, Curr Opin Neurobiol, 8, 87, 10.1016/S0959-4388(98)80012-3 Maness, 2007, Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration, Nat Neurosci, 10, 19, 10.1038/nn1827 Raveh, 2009, L1 cell adhesion molecule (L1CAM) in invasive tumors, Cancer Lett, 282, 137, 10.1016/j.canlet.2008.12.021 Schafer, 2010, L1CAM malfunction in the nervous system and human carcinomas, Cell Mol Life Sci, 67, 2425, 10.1007/s00018-010-0339-1 Fogel, 2003, L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas, Lancet, 362, 869, 10.1016/S0140-6736(03)14342-5 Zecchini, 2008, The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium, Cancer Res, 68, 1110, 10.1158/0008-5472.CAN-07-2897 Huszar, 2010, Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas, J Pathol, 220, 551, 10.1002/path.2673 Daponte, 2008, L1 (CAM) (CD171) in ovarian serous neoplasms, Eur J Gynaecol Oncol, 29, 26 Beer, 1999, Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule, J Cell Sci, 112, 2667, 10.1242/jcs.112.16.2667 Gutwein, 2003, ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles, FASEB J, 17, 292, 10.1096/fj.02-0430fje Mechtersheimer, 2001, Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins, J Cell Biol, 155, 661, 10.1083/jcb.200101099 Stoeck, 2007, L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells, Gynecol Oncol, 104, 461, 10.1016/j.ygyno.2006.08.038 Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025 Karin, 2002, NF-kappaB in cancer: from innocent bystander to major culprit, Nat Rev Cancer, 2, 301, 10.1038/nrc780 Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205 Li, 2011, The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment, Cancer Cell, 19, 429, 10.1016/j.ccr.2011.03.018 Darb-Esfahani, 2010, Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma, Histopathology, 56, 727, 10.1111/j.1365-2559.2010.03544.x Schauer, 2011, Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer, Neoplasia, 13, 393, 10.1593/neo.101720 Kiefel, 2010, L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression, Oncogene, 29, 4766, 10.1038/onc.2010.230 Gavert, 2010, Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells, J Cell Sci, 123, 2135, 10.1242/jcs.069542 Kiefel, 2011, Linking L1CAM-mediated signaling to NF-κB activation, Trends Mol Med, 17, 178, 10.1016/j.molmed.2010.11.005 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Rustin, 2003, Use of CA-125 to assess response to new agents in ovarian cancer trials, J Clin Oncol, 21, 187s, 10.1200/JCO.2003.01.223 Huszar, 2006, Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy, Hum Pathol, 37, 1000, 10.1016/j.humpath.2006.03.014 Silletti, 2004, Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion, J Biol Chem, 279, 28880, 10.1074/jbc.M404075200 Thelen, 2002, The neural cell adhesion molecule L1 potentiates integrin-dependent cell migration to extracellular matrix proteins, J Neurosci, 22, 4918, 10.1523/JNEUROSCI.22-12-04918.2002 Gavert, 2005, L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers, J Cell Biol, 168, 633, 10.1083/jcb.200408051 Meier, 2006, The adhesion molecule L1 (CD171) promotes melanoma progression, Int J Cancer, 119, 549, 10.1002/ijc.21880 Gast, 2008, The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies, Oncogene, 27, 1281, 10.1038/sj.onc.1210747 Arlt, 2006, Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment, Cancer Res, 66, 936, 10.1158/0008-5472.CAN-05-1818 Maretzky, 2005, L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth, Mol Cell Biol, 25, 9040, 10.1128/MCB.25.20.9040-9053.2005 Stoeck, 2006, A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44, Biochem J, 393, 609, 10.1042/BJ20051013 Oleszewski, 1999, Integrin and neurocan binding to L1 involves distinct Ig domains, J Biol Chem, 274, 24602, 10.1074/jbc.274.35.24602 Friedli, 2009, The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor, Int J Biochem Cell Biol, 41, 1572, 10.1016/j.biocel.2009.01.006 Strekalova, 2006, Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes, Neurobiol Aging, 27, 1, 10.1016/j.neurobiolaging.2004.11.013 Zander, 2011, Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients, BMC Cancer, 11, 181 Reidy, 2006, Activation of cell-survival transcription factor NFkappaB in L1Ig6-stimulated endothelial cells, J Biomed Mater Res A, 77, 542, 10.1002/jbm.a.30590 Gutwein, 2005, Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells, Clin Cancer Res, 11, 2492, 10.1158/1078-0432.CCR-04-1688 Sebens Muerkoster, 2007, Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells, Oncogene, 26, 2759, 10.1038/sj.onc.1210076